Company intelligence / Profile preview
Wasa Medicals
Halmstad, Halland, Swedenprobion.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ProBion tablets have been shown in clinical trials (BMJ Open Gastroenterology, July 2017) to significantly alter cancer-associated harmful bacteria and increase populations of beneficial, anti-inflammatory bacteria in the gut for colon cancer patients. Controlled-release technology results in high viability of delivered bacteria.
- Therapeutic areas
- OncologyMetabolic DisordersWomen's HealthGastroenterology
- Modalities
- Live biotherapeutic product therapy (probiotic tablets)Prebiotic therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaborations with universities, hospitals, and research institutions globally
Beyond the preview
Go deeper on Wasa Medicals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wasa Medicals.